Company intelligence / Profile preview

GI Cell

Songpa-gu, Seoul, South Koreagi-cell.com ↗

Ownership: Private
Development stage: Phase 2

Overview

GI Cell has demonstrated preclinical superiority of its mass culture and engineering platforms for allogeneic NK and regulatory T-cell therapies. The company’s lead candidates are advancing toward IND-enabling studies with a focus on cancer immunotherapy. No published clinical results yet.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Allogeneic NK cell therapy (Natural Killer cells)Treg cell therapy (Regulatory T cells)CAR-NK cell therapy (Chimeric Antigen Receptor NK cells)Multi-valent sub-unit vaccines
Industry: Biotech

Drug pipeline

2 assets

GIC-102

1 more asset in the full pipeline.

Partnerships

Optieum Biotechnologies (Japan)—scFv antibody discovery collaboration for next-gen CAR-NK developmentHK inno.N—collaboration on next-generation CAR-NK therapyLetter of intent with Turkish company to export allogeneic NK technology.

Beyond the preview

Go deeper on GI Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI Cell.